Cefalexin

CLINICAL USE


Antibacterial agent

DOSE IN NORMAL RENAL FUNCTION

250 mg every 6 hours or 500 mg every 8–12 hours; maximum 6 g dailyRecurrent UTI prophylaxis: 125 mg at night

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :365.4
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :15
  • %Excreted unchanged in urine &nbsp &nbsp : 80–90
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.35
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1/16

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : 500 mg every 8–12 hours
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 250–500 mg every 8–12 hours

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL/min
  • HDF/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=10–20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Anticoagulants: effects of coumarins may be enhanced

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

  • Use dose for normal renal function to treat urinary tract infection in ERF
  • High doses, together with the use of nephrotoxic drugs such as aminoglycosides or potent diuretics, may adversely affect renal function